文献リスト

1) Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101: 1900-20; quiz 1943

2) Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009; 44: 518-34

3) Iwakiri K, Kawami N, Sano H, et al. Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis. Dig Dis Sci. 2009; 54: 1686-92

4) Emerenziani S, Ribolsi M, Sifrim D, et al. Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with non-erosive reflux disease. Neurogastroenterol Motil. 2009; 21: 253-8

5) de Vries DR, ter Linde JJ, van Herwaarden MA, et al. Gastroesophageal reflux disease is asso­ciated with the C825T polymorphism in the G-protein beta3 subunit gene (GNB3). Am J Gastroenterol. 2009; 104: 281-5

6) Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology. 2008; 134: 696-705

7) Iwasaki E, Suzuki H, Sugino Y, et al. Decreased levels of adiponectin in obese patients with gastroesophageal reflux evaluated by video­esophagography: possible relationship between gastroesophageal reflux and metabolic syndrome. J Gastroenterol Hepatol. 2008; 23 Suppl 2: S216-21

8) Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastro­esophageal reflux disease and its complications. Ann Intern Med. 2005; 143: 199-211

9) Friedenberg FK, Xanthopoulos M, Foster GD, et al. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008; 103: 2111-22

10) El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008; 53: 2307-12

11) Gerson LB, Ullah N, Fass R, et al. Does body mass index differ between patients with Barrett's oesophagus and patients with chronic gastro-oesophageal reflux disease？ Aliment Pharmacol Ther. 2007; 25: 1079-86

12) Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Phar­macol Ther. 2005; 21: 821-7

13) de Vries DR, van Herwaarden MA, Smout AJ, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol. 2008; 103: 1349-54

14) Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006; 130: 639-49

15) Crowell MD, Bradley A, Hansel S, et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol. 2009; 104: 553-9

16) Quiroga E, Cuenca-Abente F, Flum D, et al. Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance. Surg Endosc. 2006; 20: 739-43

17) Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower eso­phageal sphincter relaxation. Gastroenterology. 2007; 132: 883-9

18) Iovino P, Angrisani L, Galloro G, et al. Proximal stomach function in obesity with normal or ab­normal oesophageal acid exposure. Neuro­gastroenterol Motil. 2006; 18: 425-32

19) Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol. 2009; 15: 1690-701

20) Iovino P, Angrisani L, Tremolaterra F, et al. Abnormal esophageal acid exposure is common in morbidly obese patients and improves after a successful Lap-band system implantation. Surg Endosc. 2002; 16: 1631-5

21) Ikramuddin S. Surgical management of gastro­esophageal reflux disease in obesity. Dig Dis Sci. 2008; 53: 2318-29

22) Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the pres­ence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. Gut. 2008; 57: 1056-64

23) Tack J, Bisschops R, Koek G, et al. Dietary restrictions during ambulatory monitoring of duodenogastroesophageal reflux. Dig Dis Sci. 2003; 48: 1213-20

24) Brillantino A, Monaco L, Schettino M, et al. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease. Eur J Gastro­enterol Hepatol. 2008; 20: 1136-43

25) Matsuzaki J, Suzuki H, Askura K, et al. Gallstones increase the prevalence of Barrett's esophagus. J Gastroenterol. 2009 Nov. 12 [Epub ahead of print]

26) Izbeki F, Rosztoczy AI, Yobuta JS, et al. Increased prevalence of gallstone disease and impaired gallbladder motility in patients with Barrett's esophagus. Dig Dis Sci. 2008; 53: 2268-75

27) Akiyama T, Inamori M, Iida H, et al. Alcohol consumption is associated with an increased risk of erosive esophagitis and Barrett's epithelium in Japanese men. BMC Gastroenterol. 2008; 8: 58

28) Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009; 136: 799-805

29) Zheng Z, Nordenstedt H, Pedersen NL, et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007; 132: 87-95

30) Nilsson M, Johnsen R, Ye W, et al. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004; 53: 1730-5

31) El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005; 54: 11-7

32) Shapiro M, Green C, Bautista JM, et al. Assess­ment of dietary nutrients that influence percep­tion of intra-oesophageal acid reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007; 25: 93-101

33) Anderson JW, Baird P, Davis RH Jr, et al. Health benefits of dietary fiber. Nutr Rev. 2009; 67: 188-205

34) Eslick GD, Talley NJ. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J Clin Gastroenterol. 2009; 43: 111-7

35) Nocon M, Labenz J, Willich SN. Lifestyle factors and symptoms of gastro-oesophageal reflux—a population-based study. Aliment Pharmacol Ther. 2006; 23: 169-74

36) Birchall MA, Bailey M, Gutowska-Owsiak D, et al. Immunologic response of the laryngeal mucosa to extraesophageal reflux. Ann Otol Rhinol Laryngol. 2008; 117: 891-5

37) Cheung TK, Lam B, Lam KF, et al. Gastro­esophageal reflux disease is associated with poor asthma control, quality of life, and psychological status in Chinese asthma patients. Chest. 2009; 135: 1181-5

38) Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006; 173: 1091-7

39) Littner MR, Leung FW, Ballard ED 2nd, et al. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005; 128: 1128-35

40) Bucknall C, Stanton A, Miller G, et al. The impact of normalization of esophageal acid profile by incremental protein pump inhibitors dosing in difficult asthma patients with proven gastro-esophageal acid reflux. J Asthma. 2009; 46: 506-11

41) American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009; 360: 1487-99

42) Asano K, Suzuki H. Silent acid reflux and asthma control. N Engl J Med. 2009; 360: 1551-3

43) Grabczak EM, Dabrowska M, Krenke R, et al. Does the established cause of chronic cough depend on diagnostic approach？ J Physiol Pharmacol. 2008; 59 Suppl 6: 285-96

44) Al-Saab F, Manoukian JJ, Al-Sabah B, et al. Linking laryngopharyngeal reflux to otitis media with effusion: pepsinogen study of adenoid tissue and middle ear fluid. J Otolaryngol Head Neck Surg. 2008; 37: 565-71

45) He Z, O'Reilly RC, Mehta D. Gastric pepsin in middle ear fluid of children with otitis media: clinical implications. Curr Allergy Asthma Rep. 2008; 8: 513-8

46) Klokkenburg JJ, Hoeve HL, Francke J, et al. Bile acids identified in middle ear effusions of chil­dren with otitis media with effusion. Laryngoscope. 2009; 119: 396-400

47) Chen MJ, Wu MS, Lin JT, et al. Gastroesophageal reflux disease and sleep quality in a Chinese population. J Formos Med Assoc. 2009; 108: 53-60

48) Dickman R, Green C, Fass SS, et al. Relationships between sleep quality and pH monitoring findings in persons with gastroesophageal reflux disease. J Clin Sleep Med. 2007; 3: 505-13

49) Cheung TK, Lam PK, Wei WI, et al. Quality of life in patients with laryngopharyngeal reflux. Digestion. 2009; 79: 52-7

50) Kusano M, Kouzu T, Kawano T, et al. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008; 43: 833-41

51) Bunch TJ, Packer DL, Jahangir A, et al. Long-term risk of atrial fibrillation with symptomatic gastroesophageal reflux disease and esophagitis. Am J Cardiol. 2008; 102: 1207-11

52) Blackshaw LA. New insights in the neural regulation of the lower oesophageal sphincter. Eur Rev Med Pharmacol Sci. 2008; 12(Suppl 1): 33-9

53) Calabrese C, Trere D, Liguori G, et al. Esophag­eal cell proliferation in gastroesophageal reflux disease: clinical-morphological data before and after pantoprazole. World J Gastroenterol. 2009; 15: 936-41

54) Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007; 67: 1521-30

55) Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic re­sponse to proton pump inhibitors. Indian J Med Res. 2008; 127: 521-30

56) Klotz U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol. 2009; 65: 1-2

57) Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002; 50: 19-24

58) Boeckxstaens GE. Reflux inhibitors: a new approach for GERD？ Curr Opin Pharmacol. 2008; 8: 685-9

59) Frisby CL, Mattsson JP, Jensen JM, et al. Inhibi­tion of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology. 2005; 129: 995-1004

60) Keywood C, Wakefield M, Tack J. A proof of concept study evaluating the effect of ADX 10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-esophageal reflux disease. Gut. 2009; 58: 1192-9

61) Hirsch DP, Holloway RH, Tytgat GN, et al. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology. 1998; 115: 1374-80

62) Boeckxstaens GE, Hirsch DP, Fakhry N, et al. Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol. 1998; 93: 1823-8

63) Beaumont H, Jensen J, Carlsson A, et al. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol. 2009; 156: 153-62

64) Peters MJ, Mukhtar A, Yunus RM, et al. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol. 2009; 104: 1548-61; quiz 1547, 1562

65) Attwood SE, Lundell L, Hatlebakk JG, et al. Med­ical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg. 2008; 12: 1646-54; discussion 1654-5

66) Chin KF, Myers JC, Jamieson GG, et al. Symp­toms experienced during 24-h pH monitoring and their relationship to outcome after laparoscopic total fundoplication. Dis Esophagus. 2008; 21: 445-51

67) Fein M, Bueter M, Thalheimer A, et al. Ten-year outcome of laparoscopic antireflux surgery. J Gastrointest Surg. 2008; 12: 1893-9

68) Grant AM, Wileman SM, Ramsay CR, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008; 337: a2664

69) Abdel-Raouf El-Geidie A, Gadel-Hak N, Fathi O. Secondary antireflux surgery. Int J Surg. 2009; 7: 44-9

70) Kala Z, Weber P, Prochazka V, et al. Tailored antireflux surgery. J Nutr Health Aging. 2008; 12: 678-80

71) Khan MA, Smythe A, Globe J, et al. Randomized controlled trial of laparoscopic Nissen versus Lind fundoplication for gastro-oesophageal reflux disease. Scand J Gastroenterol. 2009; 44: 269-75

72) Kornmo TS, Ruud TE. Long-term results of laparoscopic Nissen fundoplication due to gastroesophageal reflux disease. A ten year follow-up in a low volume center. Scand J Surg. 2008; 97: 227-30

73) Lamb PJ, Myers JC, Thompson SK, et al. Laparoscopic fundoplication in patients with a hypertensive lower esophageal sphincter. J Gastrointest Surg. 2009; 13: 61-5

74) Lee SK, Kim EK. Laparoscopic Nissen fundopli­cation in Korean patients with gastroesophageal reflux disease. Yonsei Med J. 2009; 50: 89-94

75) Bergman S, Mikami DJ, Hazey JW, et al. Endolumenal fundoplication with EsophyX: the initial North American experience. Surg Innov. 2008; 15: 166-70

76) Birk J, Pruitt R, Haber G, et al. The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study. Surg Endosc. 2009; 23: 423-31

77) Cadiere GB, Van Sante N, Graves JE, et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc. 2009; 23: 957-64

78) Bonavina L, Saino GI, Bona D, et al. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg. 2008; 12: 2133-40

79) Lamb PJ, Myers JC, Jamieson GG, et al. Long-term outcomes of revisional surgery following laparoscopic fundoplication. Br J Surg. 2009; 96: 391-7

80) Kaufman JA, Houghland JE, Quiroga E, et al. Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder. Surg Endosc. 2006; 20: 1824-30

81) Jeansonne LO 4th, White BC, Nguyen V, et al. Endo­luminal full-thickness plication and radio­frequency treatments for GERD: an outcomes comparison. Arch Surg. 2009; 144: 19-24; discussion 24

82) Chen D, Barber C, McLoughlin P, et al. System­atic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg. 2009; 96: 128-36

83) Hartmann J, Menenakos C, Ordemann J, et al. Long-term results of quality of life after standard laparoscopic vs. robot-assisted laparoscopic fundoplications for gastro-oesophageal reflux disease. A comparative clinical trial. Int J Med Robot. 2009; 5: 32-7

84) Ip S, Tatsioni A, Conant A, et al. Predictors of clinical outcomes following fundoplication for gastroesophageal reflux disease remain insufficiently defined: a systematic review. Am J Gastroenterol. 2009; 104: 752-8; quiz 759

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp